These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27910077)

  • 21. Dyslipidaemias: new mechanistic insights and the 2016 ESC Guidelines.
    Lüscher TF
    Eur Heart J; 2016 Oct; 37(39):2963-2965. PubMed ID: 27923852
    [No Abstract]   [Full Text] [Related]  

  • 22. Do we need a redefinition of the cardiovascular risk categories used in the 2019 ESC/EAS guidelines on dyslipidaemias?
    Gragnano F; Calabrò P
    Eur Heart J; 2020 Jun; 41(24):2332. PubMed ID: 32031600
    [No Abstract]   [Full Text] [Related]  

  • 23. Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias.
    ; ; ;
    Rev Esp Cardiol (Engl Ed); 2020 May; 73(5):348-353. PubMed ID: 32205101
    [No Abstract]   [Full Text] [Related]  

  • 24. PCSK9: is it fluoride for cardiology?
    King SB
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1331-2. PubMed ID: 25459045
    [No Abstract]   [Full Text] [Related]  

  • 25. A simple multiplier to calculate the impact of HDL cholesterol on cardiovascular risk estimation using SCORE.
    Descamps OS; Cooney MT; De Backer G; Graham I
    Atherosclerosis; 2012 Jun; 222(2):564-6. PubMed ID: 22560327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Spanish interdisciplinary committee for cardiovascular disease prevention and the spanish society of cardiology position statement on dyslipidemia management. Differences between the European and american guidelines].
    Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR;
    Semergen; 2015 Apr; 41(3):149-57. PubMed ID: 25450438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
    Mach F; Baigent C; Catapano AL; Koskinas KC; Casula M; Badimon L; Chapman MJ; De Backer GG; Delgado V; Ference BA; Graham IM; Halliday A; Landmesser U; Mihaylova B; Pedersen TR; Riccardi G; Richter DJ; Sabatine MS; Taskinen MR; Tokgozoglu L; Wiklund O;
    Eur Heart J; 2020 Jan; 41(1):111-188. PubMed ID: 31504418
    [No Abstract]   [Full Text] [Related]  

  • 28. [Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines].
    Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR;
    Clin Investig Arterioscler; 2015; 27(1):36-44. PubMed ID: 25444651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Consensus document of the Spanish Society of Arteriosclerosis on indications of inhibitors of PCSK9].
    Masana L; Ascaso JF; Civeira F; Pedro-Botet J; Valdivielso P; Guijarro C; Mostaza J; López Miranda J; Pintó X;
    Clin Investig Arterioscler; 2016; 28(3):164-5. PubMed ID: 26976748
    [No Abstract]   [Full Text] [Related]  

  • 30. Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines.
    Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR; ;
    Rev Esp Cardiol (Engl Ed); 2014 Nov; 67(11):913-9. PubMed ID: 25443815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comments on the ESC/EAS guidelines for the management of dyslipidaemias 2011. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology].
    Anguita M; Alegría E; Barrios V; Casasnovas JA; Escobar C; León M; Luengo E; Llisterri JL; Alonso Á; Cequier Á; Comín J; Fernández-Ortiz A; Heras M; Pan M; Worner F
    Rev Esp Cardiol; 2011 Dec; 64(12):1090-5. PubMed ID: 22107831
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clinical practice guidelines for the management of dyslipidemia in chronic kidney disease].
    Shoji T
    Nihon Jinzo Gakkai Shi; 2013; 55(7):1267-75. PubMed ID: 24288962
    [No Abstract]   [Full Text] [Related]  

  • 33. European Society of Cardiology guidelines: preoperative cardiac risk assessment and perioperative cardiac management in noncardiac surgery.
    Kristensen SD
    J Cardiovasc Med (Hagerstown); 2011 Mar; 12(3):226. PubMed ID: 21285739
    [No Abstract]   [Full Text] [Related]  

  • 34. ESC opens Brussels Bureau: the European Heart Agency.
    Tofield A
    Eur Heart J; 2013 Jun; 34(21):1527. PubMed ID: 23729698
    [No Abstract]   [Full Text] [Related]  

  • 35. The new dyslipidemia guidelines: what is the debate?
    Anderson TJ; Mancini GB; Genest J; Grégoire J; Lonn EM; Hegele RA
    Can J Cardiol; 2015 May; 31(5):605-12. PubMed ID: 25816728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.
    Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Reiner Z; Keil U;
    Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):530-40. PubMed ID: 20577089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reducing cardiovascular risk and managing dyslipidemia in women.
    Appel SJ; Floyd NA; Jones EJ
    Nurs Womens Health; 2007 Dec; 11(6):586-99. PubMed ID: 18088296
    [No Abstract]   [Full Text] [Related]  

  • 38. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
    Graham I; Atar D; Borch-Johnsen K; Boysen G; Burell G; Cifkova R; Dallongeville J; De Backer G; Ebrahim S; Gjelsvik B; Herrmann-Lingen C; Hoes A; Humphries S; Knapton M; Perk J; Priori SG; Pyorala K; Reiner Z; Ruilope L; Sans-Menendez S; Op Reimer WS; Weissberg P; Wood D; Yarnell J; Zamorano JL; Walma E; Fitzgerald T; Cooney MT; Dudina A; Vahanian A; Camm J; De Caterina R; Dean V; Dickstein K; Funck-Brentano C; Filippatos G; Hellemans I; Kristensen SD; McGregor K; Sechtem U; Silber S; Tendera M; Widimsky P; Zamorano JL; Altiner A; Bonora E; Durrington PN; Fagard R; Giampaoli S; Hemingway H; Hakansson J; Kjeldsen SE; Larsen ML; Mancia G; Manolis AJ; Orth-Gomer K; Pedersen T; Rayner M; Ryden L; Sammut M; Schneiderman N; Stalenhoef AF; Tokgözoglu L; Wiklund O; Zampelas A; ; ; ; ; ; ; ; ; ;
    Eur J Cardiovasc Prev Rehabil; 2007 Sep; 14 Suppl 2():E1-40. PubMed ID: 17726406
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort.
    Kavousi M; Leening MJ; Nanchen D; Greenland P; Graham IM; Steyerberg EW; Ikram MA; Stricker BH; Hofman A; Franco OH
    JAMA; 2014 Apr; 311(14):1416-23. PubMed ID: 24681960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy and clinical trials.
    Cusi K
    Curr Opin Lipidol; 2015 Oct; 26(5):472-4. PubMed ID: 26339771
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.